Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

NABILONE

All products: not a benefit

Other products in the same Health Canada class (A04A, A04AD) — coverage varies; not interchangeable

  • Aprepitant (Emend Tri-Pack): limited Use 452, 453
  • Granisetron (Kytril): limited Use 326, 454, Not a benefit
  • Netupitant + palonosetron (Akynzeo): limited Use 561, 562
  • Ondansetron (Zofran ODT (Tablet)): limited Use 215, 216, 217, 218, 454, 696, Not a benefit
  • Ondansetron (Zofran): not a benefit

PMS-Nabilone · DIN 02380897 · 0.25mg · capsule

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
PMS-Nabilone · DIN 02380897 Manufacturer: Pharmascience Inc.; listing date 2021-03-29 Health Canada: Marketed since 2021-01-22 · brand PMS-NABILONE · ATC A04AD11 NABILONE · form Capsule · route Oral · ingredients NABILONE 0.25 MG · company Pharmascience inc · schedule Narcotics (cdsa ii)
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86665 · Verify on the e-Formulary ↗ (DIN 02380897)

Source record
DIN 02380897: PMS-Nabilone Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 562200044; group id 668; item number 1656; lccId None; manufacturer id PMS Source form: Cap; strength: 0.25mg Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $1.4660; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02380897 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=86665
Interchangeable products
Cesamet · DIN 02312263 · not recorded Ran-Nabilone · DIN 02358077 · not recorded Teva-Nabilone · DIN 02392925 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02380897
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (56:22 Antiemetics and Antinauseants) and how they are covered

Matched class: 56:22 Antiemetics and Antinauseants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL, MECLIZINE HCL 56:22 Antiemetics and Antinauseants

APREPITANT

· 1 products · Limited Use, codes 452, 453 · strengths: 125mg & 80mg · Cap

GRANISETRON HCL

· 4 products · Listed, not a benefit (1), Limited Use, codes 91, 92, 93, 326, 454 (3) · strengths: 1mg · Tab

NETUPITANT & PALONOSETRON HYDROCHLORIDE

· 1 products · Limited Use, codes 561, 562 · strengths: 300mg & 0.5mg · Cap

ONDANSETRON HYDROCHLORIDE

· 54 products · Listed, not a benefit (5), Limited Use, codes 215, 216, 217, 218, 454, 696 (49) · strengths: 4mg, 8mg, 4mg/5mL · O/L, Tab

ONDANSETRON HCL DIHYDRATE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 2mg/mL · Inj Sol-2mL Pk, Inj Sol-4mL Pk

DOXYLAMINE SUCCINATE AND PYRIDOXINE HCL

· 4 products · General benefit · strengths: 10mg & 10mg · SR Tab

MECLIZINE HCL

· 1 products · General benefit · strengths: 25mg · Tab

DIMENHYDRINATE

· 2 products · Limited Use, codes 481 · strengths: 50mg/mL · Inj Sol (with Preservative) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 56:22
Full class listing Related classes: 56:04 Antacids and Adsorbents, 56:08 Antidiarrhea Agents, 56:12 Cathartics, 56:16 Digestants, 56:40 Miscellaneous G.I. Drugs Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS Adults: > 18 years N CESAMET® (nabilone) is indicated for the management of severe nausea and vomiting associated with cancer chemotherapy. Pediatrics: < 18 years The safety and efficacy of NCESAMET® in the pediatric population have not been established and its use is not recommended in this patient population. Geriatrics: > 65 years N CESAMET® should be used with caution in the elderly (see PRECAUTIONS). N CESAMET® Product Monograph Page 2 of 16 https://pdf.hres.ca/dpd_pm/00051389.PDF PM date: May 24, 2019 Source product: CESAMET; DIN 00548375; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Other review policies

For PMS-Nabilone: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026